RxDoctor Payments Data

Anthony Sung, MD

Hematology & Oncology · Westwood, KSNPI 1639345796

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $48,325 of the $48,785 with a category attached, or 99.1%. 7 manufacturers reported payments, led by GSK at 43.9% of the total. 2025 is the largest year on record at $33,712, more than ten times the $148 reported in 2019.

$48,785in general payments, 2019–2025

Across 10 payments — averaging $4878.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$21K
  • Janssen Research & Development, LLC$21K
  • Acrotech Biopharma Inc.$6K
  • Sanofi-aventis U.S. LLC$168
  • Eli Lilly$148
  • Genmab U.S., Inc.$124
  • plus $20 from 1 others
$205,718in research payments, 2019–2025

Across 101 payments — averaging $2036.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$206K

What the payments were for

  • Consulting fees$48,32599%
  • Food & beverage$4601%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,785 in reported general payments places this provider in the 80th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$10,344
Medicare patients
33
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Westwood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →